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Abstract
Background: Familial Adenomatous Polyposis (FAP) is caused by germline mutations in the APC
(Adenomatous Polyposis Coli) gene. The vast majority of APC mutations are point mutations or
small insertions / deletions which lead to truncated protein products. Splicing mutations or gross
genomic rearrangements are less common inactivating events of the APC gene.
Methods: In the current study genomic DNA or RNA from ten unrelated FAP suspected patients
was examined for germline mutations in the APC gene. Family history and phenotype were used in
order to select the patients. Methods used for testing were dHPLC (denaturing High Performance
Liquid Chromatography), sequencing, MLPA (Multiplex Ligation – dependent Probe Amplification),
Karyotyping, FISH (Fluorescence In Situ Hybridization) and RT-PCR (Reverse Transcription –
Polymerase Chain Reaction).
Results: A 250 Kbp deletion in the APC gene starting from intron 5 and extending beyond exon
15 was identified in one patient. A substitution of the +5 conserved nucleotide at the splice donor
site of intron 9 in the APC gene was shown to produce frameshift and inefficient exon skipping in a
second patient. Four frameshift mutations (1577insT, 1973delAG, 3180delAAAA, 3212delA) and a
nonsense mutation (C1690T) were identified in the rest of the patients.
Conclusion: Screening for APC mutations in FAP patients should include testing for splicing defects
and gross genomic alterations.
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Background
Germline mutations in the APC gene are the causative fac-
tor for the Familial Adenomatous Polyposis syndrome
which follows an autosomal dominant inheritance pat-
tern [1,2]. FAP patients develop multiple to thousands of
colonic polyps before their second decade of life.
If polyps are left untreated they give rise to colorectal can-
cer in almost all cases. The syndrome has two forms, one
referred to as classic FAP and one milder form referred to
as attenuated FAP (AFAP) [3]. Most FAP patients develop
certain extracolonic features [3,4]. Congenital Hypertro-
phy of the Retinal Pigment Epithelium (CHRPE) is
present in the majority of FAP patients. Nearly 94% of
APC germline mutations lead to a truncated protein prod-
uct. Thirty three percent of APC mutations represent non-
sense point mutations, 6% small insertions and 55%
small deletions [5].
Recently, a number of studies have demonstrated the pres-
ence of less common APC mutations in FAP patients, such
as large genomic rearrangements or splicing affecting
mutations [6,7]. It is generally noted that large rearrange-
ments are more likely to produce a classic FAP phenotype,
while splicing mutations tend to result in attenuated FAP
(AFAP) [8-13].
Large rearrangements account for up to one third of iden-
tified mutations in the BRCA1 and hMLH1 and hMSH2
genes which are responsible for other distinct or related
types of cancer, respectively [14,15]. In APC the percent-
ages are lower but according to recent reports may reach
as much as 10% of identified mutations [16]. Recently,
MLPA has been used in our laboratory, to successfully
identify large deletions in the hMSH2 and BRCA1 genes
[17,18].
Splice site mutations are a common inactivating event for
several human genes estimated to account for about 15%
of the mutations [19]. In the ATM and NF1 genes they rep-
resent about 50% of the identified mutations [20,21].
Most frequent targets of splice site mutations are the con-
sensus GT and AG donor and acceptor dinucleotides
respectively. However, several splice site mutations alter-
ing other exonic or intronic nucleotides neighboring the
consensus sites, have been described [12,21,22]. Screen-
ing the corresponding genes' cDNA elucidates most splic-
ing defects.
Nevertheless, these studies point out the need for more
intensive mutation screening than coding region and
splice junction sequencing. Finally, these studies address
the issue that such uncommon mutations may have been
underestimated due to the methods of mutation screen-
ing that have been generally used in the past decade.
In the present study, two different cases of FAP families
carrying two uncommon APC mutations are presented: a
splice site mutation on the fifth nucleotide of intron 9 and
a large genomic deletion from one chromosome 5 encom-
passing around 250 Kbp, starting in intron 5 of the APC
gene and extending beyond exon 15. We also further sup-
port our ongoing study on FAP presenting another four
frameshift mutations of the APC gene identified in four
unrelated patients.
Finally, we propose a simple algorithm for the APC
genetic testing of FAP patients based on our experience
after screening 96 individuals from 25 FAP families from
our Greek cohort.
Methods
Patients
Patients were referred to our center and selected for
genetic testing as previously described [4]. Ethical
approval was obtained from the HYGEIA – Diagnostic
and Therapeutic Center of Athens S.A. – hospital's advi-
sory committee (ref.27931/23.10.2000) and all patients
signed informed consent.
DNA and RNA isolation
Genomic DNA and RNA were purified from peripheral
blood leukocytes using standard extraction protocols, as
already described previously [4].
PCR amplification
All 16 exons (1–15, 10A) including splice junctions of
APC were amplified by PCR (Polymerase Chain Reaction)
as already described elsewhere [4,23]. The primers used
were taken from other studies [1,4].
dHPLC analysis
The WAVE DNA Fragment Analysis System (Transge-
nomic, Inc., USA) and associated WAVE-Maker™ software
were used as previously described [23].
Sequence analysis
Purification of the PCR products and automated cycle
sequencing for both strands was performed on the ABI
Prism®  310 Genetic Analyzer as previously described
[4,23].
RT-PCR
First strand synthesis was performed by denaturing
approximately 500 – 1000 ng total RNA and random hex-
amers (5 µM final concentration) for 4 min at 70°C, fol-
lowed by snap freezing on ice and addition of dNTPs (0.5
mM final concentration), 1 U/µl recombinant RNase
inhibitor (Invitrogen, The Netherlands) and 200 U MMLV
reverse transcriptase (Invitrogen, The Netherlands). The
mixture was incubated at 37°C for 1 hour followed byBMC Cancer 2005, 5:40 http://www.biomedcentral.com/1471-2407/5/40
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denaturation of the enzymes at 95°C for 5 min. 4 µl of
cDNA were used for subsequent PCR amplification. The
primers used for PCR were described by Varesco et al
(1994) [22] and amplify the cDNA region between exons
8 and 12 of the APC gene.
Multiplex Ligation-dependent Probe Amplification 
(MLPA)
MLPA was carried out using the P043 APC kit (MRC-Hol-
land, Netherlands) as instructed by the manufacturer.
Fragment analysis was carried out on the ABI Prism® 310
Genetic Analyzer using TAMRA-500 provided by the man-
ufacturer, as size standard. A peak pattern of 31 peaks
ranging in size from 130 to 400 nt is obtained [24].
Conventional cytogenetic analysis
Metaphase chromosome preparations were obtained
from peripheral blood lymphocytes using standard tech-
niques. Conventional cytogenetic analysis was carried out
using high resolution GTG banding (1200 bands). Cells
were analyzed, karyotyped and captured by computer
imaging (Cytovision system, Image Analysis, Applied
Imaging, Sunderland, UK).
FISH analysis
FISH analysis was performed as already described by Dau-
werse JG et al (1992) [25]. Cosmid probes cAPC1, cAPC2,
cAPC3 for the APC gene and MCBCD, for the MCC gene
on band 5q22.2 were simultaneously hybridized with the
telomere PACs GS-240G13 (5qter) and GS-24H17 (5pter)
for identification of chromosome 5 [26,27].
Results
Alternative splicing
In family A the proband was a young man at the age of 29
with a phenotype showing more than a hundred polyps
throughout the colon, particularly in the rectum, sigmoid
and descending colon. No polyps were found in the
esophagus, duodenum and ileum, except for one poly-
poid adenomatous lesion in the stomach. The polyps
were adenomatous, smaller than 5 millimeters and some
tubular and serrated adenomas were also observed. All
lesions showed low or medium grade dysplasia while
some serrated adenomas were mildly hyperplastic. Fun-
duscopic examination showed the absence of CHRPE.
dHPLC screening of the APC gene revealed an aberrant
elution profile for the amplicon encompassing both
exons 9 and 9A. Subsequent sequencing of that amplicon
confirmed the presence of the IVS9+5G>A mutation (Fig.
1a). In order to examine the consequences of the G to A
transition, RT-PCR was performed from total RNA
extracted from peripheral blood lymphocytes of the
proband. Total RNA from normal individuals and other
FAP patients with identified mutations in other regions of
the APC gene, were used as normal controls for this RT-
PCR. RT-PCR products were separated by non denaturing
6% PAGE and visualized by EtBr staining (Fig. 1b). Two
normal transcripts were amplified in all samples repre-
senting the two normal spliced forms of exon 9: 9 and 9A
(Fig. 1b). A novel shorter transcript was only amplified
from the proband's RNA (Fig. 1b). The corresponding
band of 336 bp was purified and sequenced. Sequence
analysis revealed an alternate transcript in which the
whole of exon 9 was missing and exon 8 was directly
joined to exon 10. This abnormal splicing results in a
frameshift and creates a STOP signal at the 16th codon of
exon 10 (Fig. 1c).
The proband's phenotype was resembling AFAP with a
late age of onset. The proband's siblings were asympto-
matic but younger than 25 years old while the proband's
parents were of normal phenotype. In order to exclude
AFAP from these individuals, they were screened by
dHPLC for the IVS9+5G>A mutation. All individuals were
of normal genotype, indicating that the mutation is de-
novo.
Large genomic rearrangements
In family B the proband was a young man at the age of 25
with a phenotype of more than a hundred polyps
throughout his colon. The patient's mother and maternal
uncle died at the age of 46 and 30 from CRC and liver can-
cer – probably metastatic, respectively. The patient's
maternal grandmother had died from CRC at the age of 45
(Fig. 2). Polyps were also present in the stomach, duode-
num and ileum. The polyps were tubular adenomas, rang-
ing in size from 5 to 15 millimeters and some with a
diameter of more than 10 mm were pediculus. All lesions
showed low or medium grade dysplasia. Funduscopic
examination showed the presence of CHRPE for this
patient.
dHPLC and sequencing of the whole APC coding region,
including splice junctions showed only the known
G4479A polymorphism for which the patient was
homozygous. Considering these results and the severity of
the patient's phenotype, MLPA was performed to screen
for genomic rearrangements which might had been unde-
tected with the conventional techniques. MLPA analysis
showed the deletion of exons 6 to 15 from one allele, in
the patient's lymphocytes, from two different blood sam-
ples (Fig. 3). The proband's asymptomatic brother tested
normal.
A large deletion, starting from intron 5 and ending down-
stream of the last APC exon, was revealed. In order to nar-
row down the 3' breakpoint, karyotype analysis was
performed on the patient's peripheral blood lymphocytes.
Karyotyping was negative excluding a deletion longerBMC Cancer 2005, 5:40 http://www.biomedcentral.com/1471-2407/5/40
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A. DNA sequence chromatogram at the splice junction between exon 9 and intron 9. Donor site is in a box and IVS9+5G>A  mutation is indicated by an arrow. Genomic structure from the region including exons 8 and 10 with exons in boxes and  introns printed as broken lines Figure 1
A. DNA sequence chromatogram at the splice junction between exon 9 and intron 9. Donor site is in a box and IVS9+5G>A 
mutation is indicated by an arrow. Genomic structure from the region including exons 8 and 10 with exons in boxes and 
introns printed as broken lines. B. The two normal splice variants 9 (exons 8-9-9A-10), 9A (exons 8-9A-10) and the abnormal 
variant missing exon 9 (exons 8–10). RT-PCR products on 6% PAGE are indicated by horizontal arrows. M: 100 bp DNA Lad-
der (New England Biolabs), p: patient sample and n: normal samples. The 336 bp abnormal product is quite evident in the 
patient sample. C. Chromatogram showing sequence of the abnormal transcript. Vertical line in chromatogram showing the 
abnormal junction between exons 8 and 10 while the box indicates the STOP signal created by the frameshift.
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than 20 Mbp. Subsequent FISH analysis confirmed that a
large portion of the APC gene was missing from one chro-
mosome 5 (data not shown). Further FISH analysis
showed that the 3' breakpoint of the deletion is lying in
the MCC gene near its 3' end (data not shown). The 5'
breakpoint lies somewhere in intron 5 which has a size of
about 12 Kbp. These data indicate that the deletion
encompasses about 250 Kbp.
APC frameshift and nonsense mutations
Four frameshift mutations (1577insT, 1973delAG,
3180delAAAA and 3212delA) of the APC gene were iden-
tified in four unrelated FAP patients and the C1690T non-
sense mutation was identified in two unrelated patients.
To our knowledge 1577insT is a novel mutation.
In two patients no mutation was identified in the APC
either screening for small insertions, deletions or point
mutations or for large genomic rearrangements.
Discussion
Alternative splicing and exon skipping
In the current study the IVS9+5G>A mutation was identi-
fied and investigated. Our patient's phenotype is resem-
bling more to AFAP than to FAP, with small polyps,
particularly in the right colon. A novel transcript is pro-
duced in the carrier's peripheral blood lymphocytes not
present in normal controls. Normal transcripts are also
present in the patient's sample, but result in lower ampli-
fication when compared to the corresponding ones of the
normal samples (Fig. 1a). The IVS9+5G>A mutation does
not alter the splicing donor site but changes a very con-
served nucleotide. Varesco et al, (1994) [22] have docu-
mented the transversion of G to T (IVS9+5G>T) at the
same point to be pathogenic. The IVS9+5G>T mutation
causes inefficient exon skipping, thus producing a milder
phenotype leading to attenuated FAP. In both cases, the
predicted truncated protein product of about 35 kDa is
not large enough to stay stable and produce a dominant
Family tree of the FAP family carrying a gross APC deletion Figure 2
Family tree of the FAP family carrying a gross APC deletion. Though no sample is available for individuals I:3, II:3 and II:4, pheno-
type, cause and age of death indicate the presence and direct transmission of the deletion identified in the proband (III:2). 
(CRC: Colorectal Cancer, Ca Li: Liver cancer).
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negative effect. The absence of CHRPE from this patient is
in agreement with the findings from Olschwang et al
(1993) [28] who concluded that patients with mutations
before exon 9 do not develop CHRPE.
Most mutations observed around the donor splice site,
that cause aberrant splicing, occur at positions -1, +1 or +2
of the intron [19]. There are few reports of mutations
altering position +5 [12,21,22]. However, the substitution
of the G residue at position +5, as well as at position +1,
would be expected to produce a significant reduction of
the base pairing stability between the 5' splice site and its
complementary region of the U1 snRNA [29,30]. U1
snRNA binding is a crucial step for the correct folding of
pre-mRNA prior to cleavage and ligation at the
spliceosome.
Moisio  et al (2002) [12], also report the IVS4+5G>C
mutation to cause skipping of exon 4 of the APC at the
mRNA level and resulting in AFAP. Based on the data pre-
sented here and in earlier studies [12,22] we conclude that
the IVS9+5G>A mutation is responsible for this patient's
AFAP phenotype and that the +5G of the donor site is a
highly conserved and functionally important nucleotide.
Large genomic rearrangements of the APC
In this FAP family the patient's phenotype is classic FAP,
in agreement with other studies [8-10] supporting that
whole gene APC deletions produce the classic FAP rather
than attenuated FAP. Considering MLPA and FISH results,
the size of the identified deletion has a length of about
250 Kbp.
The presence of CHRPE in this patient is in contradiction
to the general observation that patients with mutations
before exon 9 do not develop CHRPE. Davies et al (1995)
[31] have also reported a patient with CHRPE and a muta-
tion affecting splicing at the donor splice site of intron 4.
Wallis et al (1994) [32] state that the presence of CHRPE
depends on the size of the truncated APC protein. This
leaves a possibility of a fusion transcript as the result of
our patient's deletion to be clarified by further experi-
ments such as possibly 3' Rapid Amplification of cDNA
Ends (RACE).
Results from MLPA experiment Figure 3
Results from MLPA experiment. Chart of normalized copy number of the MLPA probes target sequences, representing APC 
exons and control regions on other chromosomes, versus size of amplified products. Two different DNA samples from the 
same patient present only one copy per cell for exons 6 to 15 supporting the presence of a large APC deletion from one 
chromosome.
Copies present
0,000000
1,000000
2,000000
3,000000
4,000000
5,000000
6,000000
0,00 50,00 100,00 150,00 200,00 250,00 300,00 350,00 400,00 450,00
Product sizes (bp)
Copy
number
APC exons: 6 7 8 9 10 11 12 13 14 15A 15B 15C
Normal
controls
Patient
DNABMC Cancer 2005, 5:40 http://www.biomedcentral.com/1471-2407/5/40
Page 7 of 8
(page number not for citation purposes)
Having analysed 25 FAP families in the past 3 years, one
family (4%) carrying a large deletion at the APC locus was
identified. This supports the notion that large genomic
events are not rare in APC but more data is needed in
order to calculate the percentage among Greek patients.
Recently, the notion that rearrangements are not so rare
for the APC but may account for more than 10% of its
mutation spectrum, is supported by studies in "APC neg-
ative" FAP patients. Su et al (2000) [6], report a percentage
of 13% and Cao et al (2001) [16] report 9% of FAP
patients carrying large rearrangements. It is possible that
the true percentage of these mutations is underestimated
due to the limitations of conventional mutation scanning
used until now.
Frameshift and nonsense APC mutations
Three small deletions, one small insertion and a nonsense
mutation were identified in this study, supporting the fact
that most APC mutations cause frameshift and usually
delete than insert nucleotides. The identified mutations
are predicted to produce truncated protein products intro-
ducing STOP codons: 1577insT at codon 535, C1690T at
codon 564, 1973delAG at codon 672 while 3180delAAAA
and 3212delA at codon 1125.
Genetic testing for adenomatous polyposis
In the past 3 years we have screened 25 families with ade-
nomatous polyposis [4,23]. To minimize time, cost and
effort, we use a simple algorithm to perform genetic test
for FAP patients. First, we carefully examine the patient's
phenotype in order to classify it as classic FAP or AFAP.
For classic FAP we start dHPLC screening of the APC from
the MCR (Mutation Cluster Region), followed by screen-
ing of the remaining 5' region of exon 15. Then we screen
the remaining exons with the following order: exons 11 to
14, exons 1 to 10A and finally the remaining exon 15.
MLPA is performed in order to identify possible gross
genomic alterations affecting the APC  gene. For AFAP
patients, screening follows the order: exons 1- 10A, 3'
region of exon 15, exons 11 – 14, 5' region and MCR of
exon 15. If no mutation is detected we finally perform the
MLPA test.
Even following the above algorithm there is a small
number of FAP patients in whom no pathogenic mutation
can be detected in the APC  gene. These cases include
patients carrying unclassified variants of these genes such
as I1307K, E1317Q and D1822V in the APC gene. Large
epidemiologic studies and functional studies with trans-
genic animals are needed to characterize these mutations.
Also, prior to examining these cases for promoter muta-
tions or expression defects, reviewing the patient and fam-
ily history is strongly recommended in order to investigate
the possibility that other genes are involved. Recently,
numerous studies point out the need for screening the
MYH gene for biallelic germline mutations in "APC nega-
tive" FAP patients [33-35]. In these patients, polyposis
arises from multiple somatic mutations that accumulate
in the APC gene due to the biallelic inactivation of the
MYH.
Conclusion
In conclusion, the combination of the above methods;
PCR, dHPLC, RT-PCR, sequencing and MLPA is a good
tool for successful genetic testing of FAP patients. It allows
the identification of common but also uncommon or rare
mutations of the APC gene. Splice site defects or gross
genomic alterations may have been underestimated by
the older testing methods and require cDNA screening
and gene rearrangement testing.
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